New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
83069 ETF · ChinaAMC Hang Seng Biotech ETF
The 83069 Exchange Traded Fund (ETF) is provided by ChinaAMC. It is built to track an index: Hang Seng Biotech Index. The 83069 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 AM UTC
LIVE
CLOSED
This fund is part ofAPAC Blended Cap1M perf.-5.35%
Last price
CNÂ¥12.45
1M perf.
-9.95%
1M flows
-€234M
AuM
€235M
E/R
0.5%
Rating
Not rated
ESG Consensus®
83069
CNÂ¥12.45
Performance & flows
Segment for quartile rank
December 12, 2025 → March 12, 2026
Create a free account to view the flows graph
83069
HK$14.37
-6.77%
APAC Blended Cap
+6.90%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -9.95%  | -6.77% | +34.06%  | +17.14% | N/A | -6.29% | +0.39% | +0.39% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
Issuer
ISIN
HK0000711199
HK0000744208
HK0000955887
AuM
€235M
E/R
0.5%
Replication rating
Not rated
ESG Consensus®
More details
NAV
3/12/2026
HK$14.37
1D NAV change
-2.11%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
30
Inception date
3/18/2021
Jurisdiction
Hong Kong
Distribution
Hong Kong
Legal structure
Unit Investment Trust
Base currency
HKD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Biotech Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
03174
1M perf.
-9.99%
E/R
1.5%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -6.77% | +34.07% | +17.14% | -39.80% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
Cayman Islands
65.16%
China
10.84%
Switzerland
10.15%
Hong Kong
8.83%
Bermuda
3.06%
Unavailable
1.96%
Sectors
Health Care
73.80%
Consumer Discretionary
5.16%
Unavailable
21.04%
Diversification
Total weight of top 15 holdings out of 30
Top 15 holdings
Data as of January 31, 2026
WUXI BIOLOGICS (CAYMAN)
CH1391448177
INNOVENT BIOLOGICS INC
AKESO INC
CSPC PHARMACEUTICAL GROUP LTD
SINO BIOPHARMACEUTICAL
HANSOH PHARMACEUTICAL GROUP CO LTD
WUXI APPTEC CO LTD
Create a free account to view top holdings
3SBIO INC
KYG7S12M1051
JD HEALTH INTERNATIONAL
CNE1000062J1
KYG9808A1058
ALIBABA HEALTH INFO TECHNOLOGY LTD
CMS
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Not rated
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
Hang Seng Biotech Index - HKD
Index ticker
HSBIO Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
ChinaAMC
ChinaAMC ID Card
Number of funds
36
Total AuM
€5.87B
Expense ratio range
0.15% - 1.2%
Average expense ratio
0.5658%
Top 5 funds by ChinaAMC
| AuM | ||
|---|---|---|
83188 | ChinaAMC CSI 300 Index ETF | €2.37B |
83403 | ChinaAMC HSI ESG ETF | €1.15B |
09472 | ChinaAMC USD Digital Money Market Fund ETF | €516M |
82839 | ChinaAMC MSCI China A 50 Connect ETF | €351M |
83088 | ChinaAMC Hang Seng TECH Index ETF | €292M |
Frequently asked questions about 83069
What does ChinaAMC Hang Seng Biotech ETF, 83069, invest in?
83069 is a Passive ETF. This ETF provides exposure to Biotechnology Equities.
Which benchmark or index does 83069 replicate?
83069 tracks the Hang Seng Biotech Index - HKD, through a full replication replication method.
What is the Total Expense ratio (TER) of 83069?
83069 carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
When was 83069 launched?
83069 was introduced to the market on March 18, 2021. It trades on Hong Kong
Who is the ETF issuer of 83069?
ChinaAMC Hang Seng Biotech ETF, 83069, is provided by ChinaAMC. Learn more about ChinaAMC here.
What is the current assets under management (AUM) of 83069?
83069 oversees €235M in assets as of March 12, 2026.
How has 83069 performed lately?
Based on data from March 12, 2026, 83069 returned -9.95% over the past month, -6.77% over the last three months and 0.39% year-to-date.
What are the latest inflows or outflows for 83069?
As of March 12, 2026, 83069 recorded net flows of -€235M over the last month and +€74M year-to-date.
Does 83069 distribute dividends?
83069 follows a distributing dividend policy, meaning it pays out income to investors. As of March 12, 2026, its 12-month trailing yield was 0.35%.
What are the main country or region exposures of 83069?
As of January 31, 2026, 83069 has significant geographic allocations in Cayman Islands, China and Switzerland.
In which sector or theme does 83069 invest in?
As of January 31, 2026, 83069 focuses largely on Health Care and Consumer Discretionary.
How many securities does 83069 hold and how diversified is it?
As of January 31, 2026, 83069 holds 30 positions in its portfolio, with 80.57% of assets concentrated in its top 15 holdings.
What are the main positions in 83069?
As of January 31, 2026, 83069 top three holdings include WUXI BIOLOGICS (CAYMAN), CH1391448177 and INNOVENT BIOLOGICS INC.
What is the base currency of 83069?
The base currency of 83069 is HKD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
